{"url_path":"/fda/drug/recalls/D-0471-2026","section_key":"summary","section_title":"DRUG Recall: PAYLESS COMPOUNDERS, LLC — Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR","topic":"fda","document":{"doc_type":"drug-recall","doc_date":"2026-03-06","source_url":"https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0471-2026%22","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"PAYLESS COMPOUNDERS, LLC"},"word_count":59,"has_tables":false,"body_markdown":"# FDA DRUG Recall: D-0471-2026\n\n**Recalling firm:** PAYLESS COMPOUNDERS, LLC\n**Classification:** Class II\n**Status:** Ongoing\n**Type:** Voluntary: Firm initiated\n**Initiated:** 2026-03-06\n**Report date:** 2026-04-22\n\n## Product\nSemaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR\n\n## Reason\nLack of Assurance of Sterility\n\n## Affected lots\nLot Number 01-27-2026@14S.5\n\n## Distribution\nOR"}